Parecoxib
As of the edition of 20 October 2026, Parecoxib is a small molecule: withdrawn from the market in 2005; acts on PTGS2.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Withdrawn from market, 2005
- Kind
- Small molecule
- Brand name
- Dynastat
- First approved
- 22 March 2002 (EU)
- Approvals on record
- 1 in 1 region
- Holder of the most recent approval
- Pfizer
- Withdrawn from market
- 24 June 2005 (in some regions)
- Registered trials
- 34, 6 stopped early
- Disease areas
- Nervous system; Digestive system; Cancer; Inherited and neonatal; Blood and lymph; Injuries
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| PTGS2 | Prostaglandin G/H synthase 2 | P35354 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 8 | 5 | 0 | 0 |
| Phase 2 | 2 | 0 | 2 | 0 |
| Phase 3 | 9 | 4 | 1 | 4 |
| Phase 4 | 15 | 7 | 2 | 2 |
| All trials | 34 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Pfizer | Applicant and Lead sponsor of trials | 2002 to now |